Comparative Pharmacology
Head-to-head clinical analysis: EFUDEX versus PICATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFUDEX versus PICATO.
EFUDEX vs PICATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, leading to depletion of thymidine triphosphate and disruption of DNA synthesis. It is incorporated into RNA as a false metabolite, interfering with RNA processing and function.
Ingenol mebutate is a diterpene ester that induces rapid necrosis of dysplastic epidermal cells following topical application. It exerts its effects through activation of protein kinase C (PKC) isoforms, leading to mitochondrial disruption, loss of membrane integrity, and cell death. Additionally, it induces a localized inflammatory response with neutrophil infiltration.
For actinic keratosis: Apply topically to lesions twice daily for 2-4 weeks. For superficial basal cell carcinoma: Apply 5% cream twice daily for 3-6 weeks. Not for systemic use.
Apply topically once daily to each lesion for 2 consecutive days per treatment course. Maximum of 1 tube per dose. Treatment area should not exceed 25 cm².
None Documented
None Documented
Terminal half-life is approximately 16 minutes (range 8-20 min) for parent drug; clinical context: due to rapid metabolism, continuous infusion or frequent dosing is required for sustained antimetabolite effect.
Terminal half-life is approximately 21 hours (range 13–48 hours) in patients with actinic keratosis; no significant accumulation observed with once-daily dosing.
Primarily hepatic metabolism to inactive metabolites; <15% excreted unchanged in urine; biliary/fecal excretion accounts for ~15%.
Primarily biliary/fecal (approximately 80% of absorbed dose), with renal excretion accounting for <5% of the dose as metabolites.
Category C
Category C
Topical Antineoplastic
Topical Antineoplastic